# A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

> **NCT05675449** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 59 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Carfilzomib
- **DRUG:** Maplirpacept

## Key facts

- **NCT ID:** NCT05675449
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-14
- **Primary completion:** 2025-07-07
- **Final completion:** 2028-02-29
- **Target enrollment:** 59 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05675449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05675449, "A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05675449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*